Search results for "Tos"

showing 10 items of 12217 documents

Bioaccessibility study of plant sterol-enriched fermented milks.

2015

The bioaccessibility (BA) of total and individual plant sterols (PS) of four commercial PS-enriched fermented milk beverages (designated as A to D) was evaluated using in vitro gastrointestinal digestion including the formation of mixed micelles. The fat content of the samples ranged from 1.1 to 2.2% (w/w), and PS enrichment was between 1.5 and 2.9% (w/w). β-Sitosterol, contained in all samples, was higher in samples A and B (around 80% of total PS). The campesterol content was C (22%) > A (7%) > B (5%). Sitostanol was the most abundant in sample D (85%). Stigmasterol was only present in sample C (33%). The greatest BA percentage for total PS corresponded to samples A and B (16–17%), follow…

0301 basic medicineDietary FiberCultured Milk ProductsCampesterolStigmasterolBiological AvailabilityModels BiologicalGastrointestinal digestionMatrix (chemical analysis)03 medical and health scienceschemistry.chemical_compoundIngredientFunctional FoodDietary CarbohydratesFood scienceMicelles030109 nutrition & dieteticsStigmasterolChemistryPhytosterolsGeneral MedicinePlant sterolDietary FatsSitosterolsGastrointestinal TractCholesterolFood FortifiedFermentationDigestionDigestionFood ScienceFoodfunction
researchProduct

The emergence of drug resistance to targeted cancer therapies: Clinical evidence.

2019

For many decades classical anti-tumor therapies included chemotherapy, radiation and surgery; however, in the last two decades, following the identification of the genomic drivers and main hallmarks of cancer, the introduction of therapies that target specific tumor-promoting oncogenic or non-oncogenic pathways, has revolutionized cancer therapeutics. Despite the significant progress in cancer therapy, clinical oncologists are often facing the primary impediment of anticancer drug resistance, as many cancer patients display either intrinsic chemoresistance from the very beginning of the therapy or after initial responses and upon repeated drug treatment cycles, acquired drug resistance deve…

0301 basic medicineDrugCancer Researchmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectTranslational researchApoptosisDrug resistanceMonoclonal antibodyBioinformatics03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansPharmacology (medical)Hedgehog ProteinsEpigeneticsProtein Kinase Inhibitorsmedia_commonPharmacologyChemotherapybusiness.industryCancerImmunotherapyProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologyInfectious DiseasesOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbusinessProteasome InhibitorsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis

2016

Only a few in vitro assays have been proposed to evaluate the steatotic potential of new drugs. The present study examines the utility of HepaRG cells as a cell-based assay system for screening drug-induced liver steatosis. A high-content screening assay was run to evaluate multiple toxicity-related cell parameters in HepaRG cells exposed to 28 compounds, including drugs reported to cause steatosis through different mechanisms and non-steatotic compounds. Lipid content was the most sensitive parameter for all the steatotic drugs, whereas no effects on lipid levels were produced by non-steatotic compounds. Apart from fat accumulation, increased ROS production and altered mitochondrial membra…

0301 basic medicineDrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectCellDrug Evaluation PreclinicalBiologyPharmacologyToxicology03 medical and health sciencesCell Line TumormedicineHumansTranscription factormedia_commonPharmacologyMembrane potentialFatty liverIn vitro toxicologyLipid metabolismLipid Metabolismmedicine.diseaseFatty Liver030104 developmental biologymedicine.anatomical_structureSteatosisToxicology and Applied Pharmacology
researchProduct

New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease

2017

Background and Aims: Drug-induced steatosis is a major reason for drug failure in clinical trials and post-marketing withdrawal; and therefore, predictive biomarkers are essential. These could be particularly relevant in non-alcoholic fatty liver disease (NAFLD), where most patients show features of the metabolic syndrome and are prescribed with combined chronic therapies, which can contribute to fatty liver. However, specific biomarkers to assess the contribution of drugs to NAFLD are lacking. We aimed to find microRNAs (miRNAs) responsive to steatotic drugs and to investigate if they could become circulating biomarkers for drug induced steatosis. Methods: Human HepG2 cells were treated wi…

0301 basic medicineDrugFarmacologiaMicroarraymedia_common.quotation_subjectBiologyPharmacology03 medical and health scienceshepatosteatosisCyclosporin amedicinePharmacology (medical)predictive biomarkermedia_commonOriginal ResearchPharmacologyFenofibratemicroRNAFatty livernon-alcoholic fatty liver diseasemedicine.diseasePatologiadrug-induced steatosis030104 developmental biologymetabolic syndrome drugDroguesSteatosisMetabolic syndromeTamoxifenmedicine.drugFrontiers in Pharmacology
researchProduct

Functional characterization of circulating tumor cells (CTCs) from metastatic ER+/HER2− breast cancer reveals dependence on HER2 and FOXM1 for endocr…

2021

Simple Summary Acquired endocrine resistance and late recurrence in patients with ER+/HER2− breast cancer are complex and not fully understood. Here, we evaluated mechanisms of acquired resistance in circulating tumor cells (CTCs) from an ER+/HER2− breast cancer patient who initially responded but later progressed under endocrine treatment. We found a switch from ERα-dependent to HER2-dependent and ERα-independent expression of FOXM1, which may enable disseminated ER+/HER2− cells to re-initiate tumor cell growth and metastasis formation in the presence of endocrine treatment. We found that NFkB signaling sustains HER2 and FOXM1 expression in CTCs in the presence of ERα inhibitors suggesting…

0301 basic medicineDrugLife sciences; biologyCancer Researchmedia_common.quotation_subjectTumor cellslcsh:RC254-282Article03 medical and health sciencesTherapeutic approach0302 clinical medicineCirculating tumor cellBreast cancerHER2-dependent FOXM1 expressionddc:570ER+/HER2− circulating tumor cellsMedicineEndocrine systemskin and connective tissue diseasesmedia_commonER+/HER2��� circulating tumor cellsbusiness.industryendocrine therapy resistancelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyApoptosis030220 oncology & carcinogenesisFOXM1Cancer researchbusiness
researchProduct

Plasmonic Nanosensors for the Determination of Drug Effectiveness on Membrane Receptors.

2016

We demonstrate the potential of the NanoSPR (nanoscale surface plasmon resonance sensors) method as a simple and cheap tool for the quantitative study of membrane protein–protein interactions. We use NanoSPR to determine the effectiveness of two potential drug candidates that inhibit the protein complex formation between FtsA and ZipA at initial stages of bacterial division. As the NanoSPR method relies on individual gold nanorods as sensing elements, there is no need for fluorescent labels or organic cosolvents, and it provides intrinsically high statistics. NanoSPR could become a powerful tool in drug development, drug delivery, and membrane studies.

0301 basic medicineDrugMaterials sciencemedia_common.quotation_subjectNanotechnologyCell Cycle Proteins02 engineering and technology03 medical and health sciencesBacterial ProteinsNanosensorEscherichia coliGeneral Materials ScienceSurface plasmon resonancePlasmonmedia_commonEscherichia coli ProteinsSurface Plasmon Resonance021001 nanoscience & nanotechnologyNanostructuresCytoskeletal Proteins030104 developmental biologyMembraneDrug developmentDrug deliveryFtsA0210 nano-technologyCarrier ProteinsProtein BindingACS applied materialsinterfaces
researchProduct

A Multi-Parametric Fluorescent Assay for the Screening and Mechanistic Study of Drug-Induced Steatosis in Liver Cells in Culture.

2017

Human hepatic cells have been used for drug safety risk evaluations throughout early development phases. They provide rapid, cost-effective early feedback to identify drug candidates with potential hepatotoxicity. This unit presents a cell-based assay to evaluate the risk of liver damage associated with steatogenic drugs. Detailed protocols for cell exposure to test compounds and for the assessment of steatosis-related cell parameters (intracellular lipid content, reactive oxygen species production, mitochondrial impairment, and cell death) are provided. A few representative results that illustrate the utility of this procedure for the screening of drug-induced steatosis are shown. © 2017 b…

0301 basic medicineDrugProgrammed cell deathmedia_common.quotation_subjectCellMitochondria LiverBiologyToxicology03 medical and health sciencesmedicineHumansCells Culturedmedia_commonchemistry.chemical_classificationReactive oxygen speciesCell Deathmedicine.diseaseLipid MetabolismFatty Liver030104 developmental biologymedicine.anatomical_structurechemistryBiochemistryLiverHigh-content screeningCancer researchHepatic stellate cellHepatocytesSteatosisChemical and Drug Induced Liver InjuryReactive Oxygen SpeciesIntracellularCurrent protocols in toxicologyLiterature Cited
researchProduct

Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach

2015

Drug development in Systemic Lupus Erythematosus (SLE) has been hindered by poor translation from successful preclinical experiments to clinical efficacy. This lack of success has been attributed to the high heterogeneity of SLE patients and to the lack of understanding of disease physiopathology. Modelling approaches could be useful for supporting the identification of targets, biomarkers and patient subpopulations with differential response to drugs. However, the use of traditional quantitative models based on differential equations is not justifiable in a sparse data situation. Boolean networks models are less demanding on the required data to be implemented and can provide insights into…

0301 basic medicineDrugSystems biologymedia_common.quotation_subjectPharmaceutical ScienceAntineoplastic AgentsDiseaseBioinformaticsAutoimmune Diseases03 medical and health sciencesmedicineAnimalsCluster AnalysisHumansLupus Erythematosus SystemicComputer Simulationmedia_commonAutoimmune diseaseLupus erythematosusbusiness.industrySystems Biologymedicine.diseaseTreatment Outcome030104 developmental biologyDrug developmentPharmacology ClinicalbusinessBiological networkSystems pharmacologyEuropean Journal of Pharmaceutical Sciences
researchProduct

A lipidomic cell-based assay for studying drug-induced phospholipidosis and steatosis

2017

Phospholipidosis and steatosis are two toxic effects, which course with overaccumulation of different classes of lipids in the liver. MS-based lipidomics has become a powerful tool for the comprehensive determination of lipids. LC-MS lipid profiling of HepG2 cells is proposed as an in vitro assay to study and anticipate phospholipidosis and steatosis. Cells with and without pre-incubation with a mixture of free fatty acids (FFA) (i.e., oleic and palmitic) were exposed to a set of well-known steatogenic and phospholipidogenic compounds. The use of FFA pre-loading accelerated the accumulation of phospholipids thus leading to a better discrimination of phospholipidosis, and magnified the lipid…

0301 basic medicineDrugmedia_common.quotation_subjectClinical BiochemistryLipidosesModels BiologicalBiochemistryMass SpectrometryAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineLipidomicsmedicineHumansPhosphatidylserinesLeast-Squares AnalysisPhospholipidsmedia_commonPhospholipidosisChemistryComputational BiologyHep G2 Cellsmedicine.diseaseIn vitroFatty LiverOleic acid030104 developmental biologyBiochemistry030220 oncology & carcinogenesislipids (amino acids peptides and proteins)Chemical and Drug Induced Liver InjurySteatosisIntracellularChromatography LiquidELECTROPHORESIS
researchProduct

Effect of colorectal cancer-derived extracellular vesicles on the immunophenotype and cytokine secretion profile of monocytes and macrophages.

2018

Abstract. Background Macrophages are one of the most important players in the tumor microenvironment. The polarization status of tumor associated macrophages into a pro-inflammatory type M1 or anti-inflammatory type M2 may influence cancer progression and patient survival. Extracellular vesicles (EVs) are membrane-bound vesicles containing different biomolecules that are involved in cell to cell signal transfer. Accumulating evidence suggests that cancer-derived EVs are taken up by macrophages and modulate their phenotype and cytokine profile. However, the interactions of cancer-derived EVs with monocytes and macrophages at various differentiation and polarization states are poorly understo…

0301 basic medicineDynaminsLipopolysaccharidesCell SurvivalCD14Macrophage polarizationLipopolysaccharide ReceptorsShort Reportlcsh:MedicineReceptors Cell Surfacecolorectal cancerBiochemistryMonocytesImmunophenotyping03 medical and health sciencesExtracellular VesiclesInterferon-gamma0302 clinical medicineCell Line TumormedicineCXCL10MacrophageHumansendocytosisSecretionLectins C-Typelcsh:QH573-671Molecular BiologyTumor microenvironmentlcsh:CytologyChemistryMonocyteMacrophageslcsh:RCell DifferentiationCell BiologyHLA-DR AntigenscytokinesCell biology030104 developmental biologymedicine.anatomical_structureMannose-Binding Lectins030220 oncology & carcinogenesisTetradecanoylphorbol AcetateCytokine secretionChemokinesColorectal NeoplasmsMannose ReceptorCell communication and signaling : CCS
researchProduct